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Abstract
Introduction Severe sepsis is the leading cause of mortality in
critically ill patients. Abnormal concentrations of inflammatory
mediators appear to be involved in the pathogenesis of sepsis.
Based on the humoral theory of sepsis, a potential therapeutic
approach involves high-volume haemofiltration (HVHF), which
has exhibited beneficial effects in severe sepsis, improving
haemodynamics and unselectively removing proinflammatory
and anti-inflammatory mediators. However, concerns have been
expressed about the feasibility and costs of continuous HVHF.
Here we evaluate a new modality, namely pulse HVHF (PHVHF;
24-hour schedule: HVHF 85 ml/kg per hour for 6–8 hours
followed by continuous venovenous haemofiltration 35 ml/kg
per hour for 16–18 hours).
Method Fifteen critically ill patients (seven male; mean Acute
Physiology and Chronic Health Evaluation [APACHE] II score
31.2, mean Simplified Acute Physiology Score [SAPS] II 62,
and mean Sequential Organ Failure Assessment 14.2) with
severe sepsis underwent daily PHVHF. We measured changes
in haemodynamic variables and evaluated the dose of
noradrenaline required to maintain mean arterial pressure above
70 mmHg during and after pulse therapy at 6 and 12 hours.
PHVHF was performed with 250 ml/min blood flow rate. The
bicarbonate-based replacement fluid was used at a 1:1 ratio in
simultaneous pre-dilution and post-dilution.
Results No treatment was prematurely discontinued.
Haemodynamics were improved by PHVHF, allowing a
significant reduction in noradrenaline dose during and at the end
of the PHVHF session; this reduction was maintained at 6 and
12 hours after pulse treatment (P = 0.001). There was also an
improvement in systolic blood pressure (P = 0.04). There were
no changes in temperature, cardiac index, oxygenation, arterial
pH or urine output during the period of observation. The mean
daily Kt/V was 1.92. Predicted mortality rates were 72% (based
on APACHE II score) and 68% (based on SAPS II score), and
the observed 28-day mortality was 47%.
Conclusion PHVHF is a feasible modality and improves
haemodynamics both during and after therapy. It may be a
beneficial adjuvant treatment for severe sepsis/septic shock in
terms of patient survival, and it represents a compromise
between continuous renal replacement therapy and HVHF.
Introduction
Severe sepsis represents the leading cause of mortality and
morbidity in critically ill patients worldwide. The sepsis syn-
drome is associated with an overwhelming, systemic overflow
of proinflammatory and anti-inflammatory mediators, which
leads to generalized endothelial damage, multiple organ failure
APACHE = Acute Physiology and Chronic Health Evaluation; CRRT = continuous renal replacement therapy; CVVH = continuous venovenous 
haemofiltration; HVHF = high-volume haemofiltration; ICU = intensive care unit; MAP = mean arterial pressure; PHVHF = pulse high-volume haemo-
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and altered cellular immunological responsiveness. Although
our understanding of the complex pathophysiological altera-
tions that occur in severe sepsis and septic shock has
increased greatly as a result of recent clinical and preclinical
studies, mortality associated with the disorder remains unac-
ceptably high, ranging from 30% to 50% [1-4].
The cornerstone of therapy continues to be early recognition,
prompt initiation of effective antibiotic therapy, source control,
and goal-directed haemodynamic, ventilatory and metabolic
support as necessary. To date, attempts to improve survival
with innovative, predominantly anti-inflammatory therapeutic
strategies have been disappointing, with the exception of
physiological doses of corticosteroid replacement therapy
[5,6] and activated protein C (drotrecogin alfa [activated]) [7]
in selected patients.
'Renal dose' haemofiltration rate of 2000 ml/hour has suc-
cessfully been used to treat acute renal failure for years [8].
This dose suffices for renal replacement therapy and can
remove inflammatory mediators; however, it does not alter
plasma levels of these mediators, suggesting that its ability to
clear inflammatory mediators is suboptimal [9]. This was
reflected in one study [10] by failure to demonstrate an
improvement in organ dysfunction and survival. Hence, the
indication for its use in septic patients was abandoned,
beyond its function to provide renal support in the presence of
renal dysfunction [11]. However, the theory that underpins
increasing plasma water exchange or higher dose haemofiltra-
tion seems reasonable.
Ronco and coworkers [12] demonstrated survival benefits by
increasing the haemofiltration dose (35 ml/kg per hour)
beyond the conventional renal dose (20 ml/kg per hour), but
no further benefit was achieved, even at higher doses (45 ml/
kg per hour), in the overall studied population. Nevertheless,
there was an improvement in survival at the highest haemofil-
tration doses in that study for the subset of patients with sep-
sis. Additionally, benefits have been demonstrated in several
animal models of sepsis. Improvements in cardiac function and
haemodynamics were replicated in these animal studies using
ultrafiltration (UF) rates up to 120 ml/kg per hour [13-16]. Sep-
tic dose haemofiltration, or high-volume haemofiltration
(HVHF), was thus conceived and applied in human sepsis.
Findings of improvements in haemodynamics with decreased
vasopressor requirements [17-19] and trends toward
improved survival [19,20] are evidence that HVHF may be effi-
cacious. Because HVHF technique requires high blood flows,
tight UF control and large amounts of expensive sterile fluids,
we proposed a new technique, namely 'pulse HVHF' (PHVHF)
[21,22]. PHVHF is application of HVHF for short periods (up
to 6–8 hours/day), providing intense plasma water exchange,
followed by conventional continuous venovenous haemofiltra-
tion (CVVH).
We hypothesized that daily 'PHVHF' may have beneficial
effects in severe sepsis by unselectively removing of proin-
flammatory and anti-inflammatory mediators, and hence
improving patient outcomes. The present study evaluates the
feasibility of PHVHF and the effect of this treatment on haemo-
dynamics, oxygenation and 28-day all-cause mortality.
Materials and methods
This is a prospective interventional study conducted in the
intensive care unit (ICU) of St. Bortolo Hospital, Vicenza, Italy.
Fifteen patients with severe sepsis receiving continuous renal
replacement therapy (CRRT) were enrolled in the study.
Patients were included in the study if they had severe sepsis
or septic shock, as defined using the criteria reported by Bone
and coworkers [23], and if they fulfilled one of the previously
reported criteria for initiating renal replacement therapy in crit-
ically ill patients [24]. Exclusion criteria were age less than 18
years, death imminent within 24 hours, and very high weight
(>140 kg). All patients were treated using the same, recently
developed management guideline for severe sepsis and septic
shock [25]. All except one patient were receiving mechanical
ventilation because of respiratory failure. Broad spectrum anti-
biotics were given to all patients and were altered according
to blood culture and sensitivity findings.
Eight out of 15 patients received activated protein C (drotrec-
ogin alfa [activated]). The drug was not used in seven patients:
one had underlying ruptured abdominal aortic aneurysm; the
second was admitted because of multiple fractures and
severe head trauma; the third had an Acute Physiology and
Chronic Health Evaluation (APACHE) II score less than 25 at
admission; and the remaining four had severe thrombocytope-
nia (<15,000/mm3) and/or impaired coagulation (international
normalized ratio >3.0). The use of activated protein C (drotrec-
ogin alfa [activated]) in approximately 50% of the patients
included might therefore have contributed to any improved
outcome identified. Clinical data are summarized in Table 1.
The APACHE II score, Simplified Acute Physiology Score
(SAPS) II, and Sequential Organ Failure Assessment score
were calculated from physiological measurements obtained
during the first 24 hours of ICU admission. Expected mortality
rates for APACHE II and SAPS II scores were computed using
the logistic regression calculations suggested in the original
reports [26,27]. The study protocol was approved by the hos-
pital ethics committee.
Description of pulse high-volume haemofiltration 
technique
PHVHF was performed using a multifiltrate CRRT machine
(Fresenious Medical Care, Bad Hamburg, Germany). This
recently designed machine provides high-precision scales
(equipped with software for online continuous testing and high
capacity) and powerful heating systems for maintaining theAvailable online http://ccforum.com/content/9/4/R294
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large volumes of infusion solution at sufficiently high
temperature.
Vascular access was obtained with 14-Fr central venous
haemodialysis catheter. Blood flow rates of 250–300 ml/min,
as permitted by the access, were used to achieve a filtration
fraction of 20–25% and to prevent premature clotting of extra-
corporeal circuit.
PHVHF was performed using a UF rate of 85 ml/kg per hour
for 6 hours/day followed by standard continuous venovenous
haemofiltration (CVVH; UF rate 35 ml/kg per hour) for 18
hours, resulting in a cumulative dose of approximately 48 ml/
kg per hour. Treatments were given on a daily basis, and were
terminated if the patient died or if the physician considered the
septic process to have ended and the patient's clinical param-
eters improved.
Commercially available bicarbonate-buffered replacement
fluid containing sodium 142 mmol/l, potassium 2 mmol/l, chlo-
ride 113.5 mmol/l, bicarbonate 32 mmol/l and calcium 1.75
mmol/l (Bi-intensive; B-Braun, Bologna, Italy) was used at a
ratio of 1:1 in simultaneous pre-dilution and post-dilution.
Additional potassium and phosphate were administered intra-
venously to prevent hypokalaemia and hypophosphataemia. A
highly biocompatible synthetic membrane with surface area of
1.8–2 m2 was also utilized. Anticoagulation was initiated with
1000–2000 IU bolus injection of heparin followed by an infu-
Table 1
Clinical features of patients with septic shock/severe sepsis treated with pulse high volume hemofiltration
Age (years)/sex/
body weight (kg)
Number of 
treatments
Diagnosis Microbiology Number of organ 
failures
APACHE II 
scorea
SAPS II scorea SOFA score 28-day survival
66/M/77 1 CHF, septic shock Negative 4 35 (83%) 79 (92%) 14 D
62/M/70 2 Lobar pneumonia Negative 4 27 (61%) 53 (53%) 11 D
77/M/70 2 Ruptured abdomonal 
aortic aneurysm, 
pancreatitis
Nonfermentative 
Gram-negative 
bacilli
4 32 (76%) 53 (53%) 14 D
37/M/87 5 Necrotizing fasciitis Negative 5 29 (67%) 58 (64%) 17 A
69/F/68 3 Kidney transplant, 
disseminated 
candidiasis, 
septicaemia 
(uncertain source)
Candida glabrata, 
coagulase-negative 
Staphylococcus
4 34 (81%) 86 (95%) 13 A
54/M/80 2 Bronchopneumonia Negative 3 23 (46%) 46 (37%) 12 A
54/F/45 2 Myelodysplasia, 
acute endocarditis
Staphylococcus 
aureus, 
Escherichia coli
5 29 (67%) 55 (58%) 17 D
58/F/65 3 Obstructive 
uropathy, 
pyelonephritis
Escherichia coli 4 28 (64%) 46 (37%) 15 A
64/M/80 1 Exfoliative dermatitis, 
erysipilas
Haemolytic 
Streptococcus 
group A
4 39 (90%) 82 (94%) 16 D
74/F/90 2 Nosocomial 
pneumonia, catheter-
related sepsis
Pseudomonas 
aeruginosa, 
coagulase-negative 
Staphylococcus
4 33 (79%) 61 (70%) 14 A
43/F/63 6 Kidney transplant, 
disseminated 
candidiasis, UTI
Escherichia coli, 
Candida albicans
3 26 (57%) 32 (42%) 11 A
33/M/85 3 Multiple trauma, 
infected wound
Coagulase-
negative 
Staphylococcus
5 31 (73%) 70 (84%) 13 D
69/F/82 2 Multiple myeloma, 
peritonitis
Nonfermentative 
Gram-negative 
bacilli
4 33 (79%) 74 (88%) 14 D
44/F/83 8 Kidney transplant, 
septicaemia 
(uncertain source)
Pseudomonas 
aeruginosa, 
Enterococcus 
faecalis
4 36 (85%) 68 (81%) 16 A
59/F/63 9 Rheumatoid arthritis, 
pneumonia
Streptococcal 
pneumonia
5 33 (79%) 67 (80%) 16 A
aShown in parentheses is the predicted chance of hospital mortality. A, alive; APACHE, Acute Physiology and Chronic Health Evaluation score; 
CHF, congestive heart failure; D, died; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; UTI, urinary tract 
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sion of 250–500 IU/hour. Net fluid removal was set according
to the patient's condition and clinical need.
Measurements
Haemodynamic monitoring was done using a thermodilution
pulmonary artery catheter with continuous cardiac output
monitoring (Vigilance; Edwards Lifesciences, Irvine, CA,
USA). A radial or a femoral arterial catheter was used to meas-
ure blood pressure and obtain arterial blood for blood gas
analysis. Systolic blood pressure, mean arterial pressure
(MAP), body temperature, heart rate, cardiac index and
noradrenaline (norepinephrine) dose required to maintain
MAP above 70 mmHg were measured immediately before
PHVHF, mid-PHVHF, immediately after PHVHF, and 6 hours
and 12 hours after completion of the PHVHF session. The
bedside nurse was instructed to maintain MAP above 70
mmHg by adjusting the dose of noradrenaline infused. pH,
partial oxygen tension and bicarbonate were measured using
a clinical blood gas analyzer (Rapidpoint 400; Bayer Health-
Care, Newbury, UK) at similar time intervals.
Blood samples were also collected at immediately before initi-
ation of treatment, immediately on discontinuation of PHVHF
and 12 hours after the session had ended, in order to measure
blood urea nitrogen, creatinine and electrolytes. Observed
mortality was recorded during the day on which patients
received PHVHF and at 28 days.
Data analysis
One-sample Kolmogorov–Smirnov test was utilized to assess
whether the distribution of haemodynamic and metabolic vari-
ables were normal. Normally distributed data are presented as
means ± standard deviation, and differences of serially meas-
ured variables were analyzed using analysis of variance for
repeated measurements with Bonferroni correction. For non-
normally distributed variables, results are reported as medians
with 25th to 75th percentile range, and Friedman's two-way
analysis of varience with post hoc Wilcoxon signed rank test
was used to identify whether changes had occurred over time.
Comparison between expected mortality (based on APACHE
II and SAP II scores) and observed mortality was done using
the standardized ratio and 95% confidence interval calculated
by dividing the observed by expected mortality [28]. P < 0.05
was considered statistically significant.
Results
Patient outcomes
Of the 15 patients enrolled, 50 PHVHF treatments were per-
formed on a daily basis. The mean number of treatments per
patient was 3.4 (1–9). No treatment was prematurely discon-
tinued because of extracorporeal circuit clotting or high pres-
sure problems. Demographic data are presented in Table 1.
The observed patient hospital mortality was 46.7%, as com-
pared with a rate of 72% predicted by APACHE II and 68%
predicted by SAPS II severity scores. Hospital mortality ratios
(95% confidence interval) [28] were 0.65 (0.48–0.87) and
0.69 (0.51–0.92), as compared with the expected mortality
calculated from APACHE II and SAPS II scores, respectively.
With respect to causes of death, one patient died from acute
myocardial infarction with cardiogenic shock during day 7 of
ICU admission. The second patient, with acute endocarditis,
underwent PHVHF for 2 days and all vasopressors (noradren-
aline, adrenaline and dopamine) were discontinued on day 3.
Table 2
Baseline demograpic and physiological variables stratified by outcome (28-day survival)
Variables Survivor (n = 8) Nonsurvivor (n = 7) P
Age (years) 55 ± 13 61 ± 14 NS
Body weight (kg) 75 ± 11 73 ± 13 NS
SBP (mmHg) 98 ± 20 120 ± 32 NS
MAP (mmHg) 68 ± 12 72 ± 13 NS
CI (l/min per m2) 4.1 ± 1.1 2.7 ± 1.0 NS
PaO2/FiO2 ratio 216 ± 99 172 ± 49 NS
APACHE II score 30.3 ± 4.5 32.2 ± 3.9 NS
SAPS II score 58.0 ± 16.6 66.6 ± 12.7 NS
SOFA score 14.3 ± 2.1 14.1 ± 2.0 NS
Number of organ failures 4.0 ± 0.8 4.3 ± 0.5 NS
Number of PHVHF treatments 4.8 ± 2.7 1.9 ± 0.7 0.02
Values are expressed as mean ± standard deviation. APACHE, Acute Physiology and Chronic Health Evaluation score; CI, cardiac index; MAP, 
mean arterial pressure; PaO2/FiO2, arterial oxygen tension/fractional inspired oxygen; PHVHF, pulse high-volume haemofiltration; SAPS, 
Simplified Acute Physiology Score; SBP, systolic blood pressure; SOFA, Sequential Organ Failure Assessment.Available online http://ccforum.com/content/9/4/R294
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Unfortunately, the patient had cardiogenic shock from a rup-
tured aortic valve on day 7 and died on day 9 after admission.
The third patient died because her underlying disease was
multiple myeloma grade IIIb, which did not respond to chemo-
therapy, and the physician decided to withhold the treatment,
in accordance with hospital policy, on day 9 after admission.
Only the remaining four patients died from refractory septic
shock.
Table 2 summarizes baseline demographic and physiological
parameters, stratifying patients by whether they were alive at
28 days. Before initiation of PHVHF there were no significant
differences between survivors and nonsurvivors at 28 days
with respect to age, body weight, MAP, cardiac index, oxygen-
ation, severity scores (APACHE II, SAPS II and Sequential
Organ Failure Assessment) and number of organ failures.
Interestingly, the mean number of PHVHF treatments per
patient was significantly higher in the group of survivors (4.8 ±
2.7) than in the nonsurvivor group (1.9 ± 0.7; P = 0.02).
Haemodynamic outcomes
All patients except three received noradrenaline at the start of
PHVHF treatment, with a median dose of 48 µg/min (Table 3).
In fact, dopamine is generally the first-choice vasoactive/ino-
tropic agent in our unit; however, once the dopamine infusion
has exceeded 10 µg/kg per min or low systemic vascular
resistance is identified by pulmonary artery catheter, our policy
is to initiate noradrenaline and taper dopamine. As a result,
noradrenaline was the sole vasoactive agent in one patient
only. The remaining three patients were receiving dopamine
with or without dobutamine at the initiation of PHVHF therapy.
The median number of concurrently administered vasopres-
sors per patient before PHVHF was 2, and this did not change
after PHVHF. No patients developed threatening hypotension
during pulse therapy, and none needed de novo institution of
vasopressors during this treatment.
Haemodynamic changes are shown in Table 3. MAP before
PHVHF was 82 ± 18 mmHg, after PHVHF it was 87 ± 18
mmHg, and 12 hours after PHVHF it was 87 ± 22 mmHg (P
= 0.2). However, systolic blood pressure increased signifi-
cantly over time (pre-PHVHF 124 ± 26 mmHg, mid-PHVHF
127 ± 22 mmHg, post-PHVHF 133 ± 25 mmHg, 6 hours after
PHVHF 133 ± 24 mmHg, and 12 hours after PHVHF 133 ±
26 mmHg; P = 0.04). As expected, MAP and cardiac index did
not change significantly over time during PHVHF and after
treatment, and MAP was maintained at the target levels in
accordance with the study protocol (Table 3). The dose of
noradrenaline required for maintenance of target MAP
decreased significantly by the mid-point of the PHVHF
session, and this decrease was maintained at 6 and 12 hours
after treatment (P = 0.001; Table 3 and Fig. 1).
By setting the temperature of the replacement fluid at around
38.5–39°C, body temperature was constant during pulse
treatment (Table 3). Positive fluid balance on the day before
PHVHF (1374 ± 2618 ml/day) was not different from that dur-
ing the day on which patients underwent PHVHF (1514 ±
2548 ml/day; P = 0.9). Oxygenation (arterial oxygen tension/
fractional inspired oxygen ratio) did not change over time.
Solute control and renal outcomes
Seven out of eight survivors underwent CVVH after the termi-
nation of daily PHVHF treatments because of renal failure. In
one survivor renal function recovered by the time of cessation
of daily PHVHF. All except two kidney transplant recipients (in
whom the graft was lost because of septic shock) could be
withdrawn from renal replacement therapy and had complete
renal recovery.
Four nonsurvivors at 28 days with refractory septic shock died
while they were still receiving daily PHVHF. As mentioned
above, three nonsurvivors died for reasons other than septic
Table 3
Effects of pulse high-volume haemofiltration on haemodynamic variables
Variables Pre-PHVHF Mid-PHVHF End-PHVHF 6 hours after PHVHF 12 hours after PHVHF P
Noradrenaline Dose (µg/min) 48 (0–114) 40 (0–97)* 40 (0–93) 40 (0–69)* 33 (0–67)** 0.001
SBP (mmHg) 124.32 ± 25.63 126.64 ± 22.10 133.00 ± 24.55 133.06 ± 23.88 133.16 ± 26.15 0.04
MAP (mmHg) 82.16 ± 18.31 85.02 ± 18.82 86.88 ± 17.56 87.76 ± 20.65 87.26 ± 22.05 NS
CI (l/min per m2) 3.4 ± 1.1 3.4 ± 1.2 3.5 ± 1.0 3.5 ± 1.1 3.5 ± 1.2 NS
HR (beats/min) 97.28 ± 25.53 99.62 ± 22.94 100.06 ± 21.79 99.94 ± 20.71 95.62 ± 20.66 0.04
Temperature (°C) 36.7 ± 1.0 36.8 ± 0.8 36.8 ± 0.8 36.9 ± 0.8 36.7 ± 0.9 NS
PaO2/FiO2 230.9 ± 109.1 232.8 ± 104.4 243.0 ± 105.6 230.2 ± 109.9 234.6 ± 106.4 NS
Normally distributed values are reported as mean ± standard deviation, and the statistical test used was analysis of variance for repeated 
measurements. Non-normally distributed values are reported as median (25th to 75th percentile), and P value was determined using Friedman's 
two-way analysis of varience with post-hoc Wilcoxon signed rank test. *P < 0.05, **P < 0.01 versus baseline. HR, heart rate; CI, cardiac index; 
MAP, mean arterial pressure; PaO2/FiO2, arterial oxygen tension/fractional inspired oxygen; PHVHF, pulse high-volume haemofiltration; SBP, 
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shock and were treated with CVVH following improvement in
their haemodynamic parameters and cessation of PHVHF.
Solutes and acid base status before and after PHVHF are pre-
sented in Table 4. Daily Kt/V was 1.92 ± 0.29. As expected,
serum blood urea nitrogen and creatinine levels diminished
greatly after pulse treatment (P < 0.0001; Table 4). Daily urine
output on the day before treatment (median 310 ml, range 75–
1916 ml) did not differ from that on the day of initiation of
PHVHF treatment (median 268 ml, range 77–1905 ml).
Discussion
The sepsis syndrome is associated with an overwhelming, sys-
temic overflow of proinflammatory and anti-inflammatory medi-
ators, which leads to generalized endothelial damage, multiple
organ failure and altered cellular immunological responsive-
ness. The complex inflammatory network involved is
redundant, synergistic and acts like a cascade. It includes
mediators with autocrine and paracrine actions, as well as cel-
lular and intracellular components. A large number of proin-
flammatory mediators, including tumour necrosis factor-α,
interleukin-1, interleukin-6, platelet-activating factor and nitric
oxide, play important roles in the cascade, but attempts to
improve survival in human trials using innovative, predomi-
nantly anti-inflammatory therapeutic strategies have been dis-
appointing [29]. Almost paralleling the surge in
proinflammatory mediators, there is a rise in anti-inflammatory
substances, resulting in induction of a state of immunoparaly-
sis or monocyte hyporesponsiveness [30]. Both proinflamma-
tory and anti-inflammatory factors become upregulated and
interact with each other, leading to various rises in mediator
levels that change over time. Neither therapies directed at sin-
Figure 1
Haemodynamic variables Haemodynamic variables. Variables were recorded during the pulse high-volume haemofiltration (PHVHF) session, and 6 hours and 12 hours after 
completion of the session. Noradrenaline (norepinephrine [NE]) requirement decreased significantly during treatment, and this reduction persisted at 
6 hours and 12 hours after treatment (P = 0.0001). *P < 0.05 and aP < 0.01 for difference between pre-PHVHF and other measures over time. 
Sytolic blood pressure (SBP) increased significantly during treatment, and this was maintained 6 hours and 12 hours after treatment (P = 0.04). All 
reported values are means.
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gle mediators nor single-dose interventions therefore seem
appropriate, in part because of a discrepancy between the
biological timing of the syndrome and the clinical timing of
symptoms.
CRRT has made extracorporeal treatment possible in septic
patients even when they are haemodynamically unstable; such
treatment is given to balance hypercatabolism and fluid over-
load. In addition, 'high volume' and convective modalities have
the advantage of removing higher molecular weight sub-
stances, which include many inflammatory mediators. Multiple
animal studies [13-16] have shown a beneficial effect of HVHF
on survival in endotoxaemic models. Recent studies in humans
[17-19] have demonstrated that HVHF improves haemodyam-
ics, with decreased vasopressor requirements.
A daily PHVHF regimen was utilized as the intervention in the
present study for the following reasons. First, the very high UF
volume requires very close surveillance, which is difficult to
maintain over 24 hours. Second, solute kinetics may render
high volumes useless after a few hours because of saturation
of membrane adsorption [17,31]. Third, standard CVVH (UF
rate 35 ml/kg per hour) may help to maintain the effect of pulse
therapy and prevent post-treatment rebound from sudden
changes. Instead of using a fixed dose (i.e. UF rate 6 l/hour),
we applied a dose of 85 ml/kg per hour during pulse treatment
because body size is the main predictor of patient outcome
[12,18]. Additionally, 'continuous' removal of soluble media-
tors may be the most logical and best approach to a complex
and lengthy process such as sepsis; we therefore performed
PHVHF on a daily basis and terminated treatment when
haemodynamic variables improved. We hypothesized that
beneficial haemodynamic effects would be achieved during
PHVHF, and that these effects would be perpetuated after
cessation of the pulse treatment by standard CVVH. We also
hypothesized that they would be accompanied by improve-
ment in oxygenation and reduction in mortality. The present
pilot study in patients with severe sepsis/septic shock was
conducted to test our hypotheses.
Overall, PHVHF was well tolerated by critically ill patients and
appeared to offer many of the benefits conferred by continu-
ous HVHF [19] while avoiding its drawbacks. Six to eight
hours PHVHF during the daytime was widely accepted by the
ICU nursing staff because it reduced the labour intensity of the
protocol during the night shift. No treatment was prematurely
discontinued because of extracorporeal circuit clotting or high
pressure problems. It appears that PHVHF is a feasible modal-
ity and can safely be performed on a daily and prolonged
basis. The greatest duration of treatment in any patient our
study was 9 days. The most clinically relevant finding that
emerged from our investigation is that adjuvant PHVHF in sep-
tic shock patients is associated with improvement in
haemodynamic parameters (Fig. 1), permitting a significant
reduction in vasopressor requirements as soon as halfway
through and at the end of the PHVHF session, and this was
maintained at 6 hours and 12 hours after treatment. The
haemodynamic benefits of short-term HVHF regimens were
recently demonstrated by Cole and coworkers [17] (UF rate 6
l/hour, duration 8 hours) and Honore and colleagues [18] (UF
rate 8.75 l/hour, duration 4 hours). We proved that this bene-
ficial hemodynamic effect can be maintained after HVHF by
continuing with standard dose CVVH (UF rate 35 ml/kg per
hour). Indeed, in practice our regimen could be adjusted on
the basis of the individual patient's clinical response.
Several mechanisms are potentially responsible for the
reduced need for pressor therapy with PHVHF. For mediator-
independent factors, we were unable to demonstrate any
differences in body temperature and arterial pH before and
after PHVHF, including 12 hours after treatment. It is clear that
cooling-induced vasoconstriction and correction of severe aci-
dosis cannot account for this positive haemodynamic effect.
The daily fluid balance on the day before initiation of PHVHF
and that on the day of intervention were similar. Based on
these findings, we argue that PHVHF permits continuous
removal of soluble vasodilatory mediators or molecules identi-
fied in sepsis by either convection or adsorption, resulting in
reduction in vasopressor requirements.
Unlike recent studies conducted by Honore and coworkers
[18] and Joannes-Boyau and colleagues [19], we was unable
to demonstrate any benefit of HVHF on cardiac index. The
possible explanation for this is that we recruited patient at an
Table 4
Effects of pulse high-volume haemofiltration on metabolic variables
Variables Pre-PHVHF End-PHVHF 12 hours after PHVHF P
Blood urea nitrogen (mg/dl) 102.5 (80.5–150.5) 86.0 (68.5–109.0)* 94.0 (69.0–138.0)* <0.0001
Creatinine (mg/dl) 2.5 (1.4–3.5) 1.8 (1.2–2.9)* 1.9 (1.2–2.8)* <0.0001
pH 7.38 (7.34–7.45) 7.40 (7.35–7.46) 7.39 (7.33–7.45) NS
HCO3
- (mmol/l) 23.9 (21.3–25.9) 24.0 (22.4–25.4) 24.0 (22.1–25.7) NS
Reported values are median (25th to 75th percentiles); P values determined using Friedman's two-way analysis of varience with post-hoc 
Wilcoxon signed rank test. *P < 0.0001 versus baseline. PHVHF, pulse high volume haemofiltration.Critical Care    Vol 9 No 4    Ratanarat et al.
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earlier time point in septic shock (i.e. during hyperdynamic
state); the mean cardiac index of our patients was 3.4 l/min per
m2, whereas those in the other two studies were less (2.0 l/min
per m2 [18] and 2.9 l/min per m2 [19]). The aim of haemody-
namic support in our sepsis patients was to maintain condiac
index at 2.5 l/min per m2 or above because the studies that
attempted to maintain a supraphysiologic cardiac index of
above 4.0 to 4.5 l/min per m2 have not shown consistent ben-
efit [32,33]. Interestingly, this indicates that the improved
haemodynamics and decreased vasopressor requirement
conferred by daily PHVHF are clinically significant even during
hyperdynamic septic shock.
Although it is beyond the scope of this report to provide a full
comparison of mortality rates between standard sepsis treat-
ment and such treatment combined with PHVHF, it appears
that PHVHF may have beneficial immunomodulatory effects
with prolonged daily use, especially with respect to patient
outcome. The 28-day all-cause mortality was 47%, as com-
pared with 72% as predicted by APACHE II and 68% as pre-
dicted by SAPS II severity scores. This is consistent with the
findings of another study [19], in which 96 hours of continuous
HVHF was given to patients with septic shock (46% observed
and 70% predicted mortality rate). In fact, of the seven deaths
at 28 days in our study, only four were attributable to refractory
septic shock. How long would it take for a clinically relevant
benefit to manifest? Tailoring our daily PHVHF regimen
according to clinical response should permit sufficient dura-
tion of HVHF. In addition, because absolute or relative con-
traindications were met in seven patients, only the remaining
eight patients in the present study received activated protein
C (drotrecogin alfa [activated]) – a drug that has shown the
benefit in terms of 28-day mortality in recent trials [7]. How-
ever, we can state that PHVHF is feasible and, as a treatment
for severe sepsis/septic shock, can affect physiological end-
points. In terms of mortality, the only way to demonstrate the
effect of PHVHF in this population is to conduct a prospective,
randomized, controlled study on a larger scale. Nevertheless,
we can hypothesize that the use of activated protein C (drot-
recogin alfa [activated]) in 50% of the population might have
contributed to the improved outcome. If so, then the combina-
tion of activated protein C (drotrecogin alfa [activated]) and
PHVHF might be particularly useful.
The present study is limited by the fact that the population was
highly heterogeneous, relatively small and reflective of patients
seen in a single center. We did not measure mediator levels in
plasma and in the UF over time, which might have helped to
explain the mechanisms of mediator removal. However, the
nonselective, simultaneous removal of different mediators
demonstrated by a reduction of the circulating cytokines or an
increase their levels in the UF may not necessarily implicate as
the gold standard of blood purification for sepsis patients. A
more effective strategy would be to attempt to influence the
functional responses of cells that are implicated in the patho-
genesis of sepsis. Such approaches are under evaluation, and
findings reported in a preliminary paper [21] are encouraging.
Also, we did not evaluate removal of sedative drugs with
vasodilatory effect, such as midazolam and sufentanil. For eth-
ical reasons, we could not conduct the trial in sepsis patients
who did not have acute renal failure. In the context of acute
renal failure in sepsis, it is clear that metabolic compounds
partly accumulate as a consequence of the loss of renal func-
tion. Uraemic toxins rapidly accumulate in tissues and plasma,
and they may be responsible for the immune dysregulation
associated with sepsis.
Conclusion
In summary, PHVHF appears to be feasible and is a promising
technique for the treatment of severe sepsis. We demon-
strated a clinically and statistically significant beneficial effect
of this therapy on vasopressor requirements during treatment
and after therapy. It may be a beneficial adjuvant treatment for
severe sepsis/septic shock in terms of patient survival, and it
represents a compromise between CRRT and HVHF. Further
confirmation is required in large, properly designed clinical tri-
als to establish the benefit of PHVHF.
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Key messages
•  PHVHF represents a feasible compromise between 
CRRT and HVHF, in which HVHF is applied for short 
periods of up to 6–8 hours/day and followed by stand-
ard dose CVVH.
•  PHVHF, when applied in patients with septic shock/
severe sepsis, can achieve beneficial effects on vaso-
pressor requirements.
•  PHVHF applied on the daily basis and tailored accord-
ing to clinical response may represent a beneficial adju-
vant treatment for severe sepsis/septic shock in terms 
of patient survival.Available online http://ccforum.com/content/9/4/R294
R302
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